Imagion CEO Bob Proulx discusses the company’s path to first-in-human trials plus early discussions with potential partners and strategic investors in this Margermarket article.
Read the article.
Positive independent review sets priority path to market for MagSense® Technology
February 5, 2023
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance